BioNTech SE (NASDAQ: BNTX) reviewed 10-14-2020
Market Cap: $20.2 Billion (USD) Share Price: $86.86 (USD)
Shares outstanding: 232,304,000
Cash & cash equivalents: $519 M (Euro) at 30 June 2020
Debt: $19.45 M (Euro) via Deutsche Bank AG
Insiders: 1.26% Institutional: 36 holders own approx. 4% of the float
Website: biontech.de
Investor Presentations: https://investors.biontech.de/events-and-presentations
CEO: Ugur Sahin HQs: Mainz, Germany
BioNTech was founded in 2008 to seek immunotherapy genetic treatments for cancer
The company is in collaboration, with Pfizer, since March 2020 to develop a COVID-19 vaccine
Focused on oncology with 20+ products in the pipeline; 10 are currently in clinical trials
Has 1300 employees and seven collaborative partnerships
Phase 1 Trials:
- BNT111, BNT112, BNT113: Melanoma, Prostate cancer, Head & Neck cancers
- BNT114, BNT115, BNT116: Breast cancer, ovarian cancer, and NSCLC
- BNT122, BNT131: 1L Melanoma, Locally advanced or metastatic solid tumors, & solid tumors
Phase 3 trials:
- BNT162: COVID-19 in Phase 3 development with Pfizer, and Fosun Pharmaceutical (China)
Collaboration: Pfizer, Genentech, Penn, Sanofi, Global, Genmab, Genevant
, mainly as a result of the COVID-19 vaccine collaboration with Pfizer
Bottom Line:
- My top-pick Biotech stock is BioNTech, which is the Moderna of Germany and Europe.
- I like the fact they collaborate with Pfizer for manufacturing scale by contributing multiple mRNA vaccine candidates as part of its leading BNT162 COVID-19 program. That has helped BNTX shares increase by 572% in the past year